Kevin Lang | Senior Research Scientist, Laboratory Services Bioanalytical Lab
PPD, part of Thermo Fisher Scientific

Dr. Kevin Lang is a recognized leader in immunophenotyping for clinical trials and spectral flow cytometry, particularly in cell and gene therapies like CAR-T. His award-winning research includes a 2024 WRIB Poster and an AAPS PharmSci360 presentation regarding CAR-T therapy. Dr. Lang is excited about developing immunotherapies,  how to track immune responses and cell therapies in clinical trials, and the benefits of spectral flow cytometry for pharmaceutical and biotech companies in need of complex immune monitoring data.
As an immunologist for the PPD Clinical Research business of Thermo Fisher Scientific, Dr. Lang’s primary responsibility is to manage the development, validation and analysis of clinical flow cytometry assays, including both conventional and spectral techniques. These techniques are crucial for monitoring drug products throughout clinical trials. His responsibilities extend to providing scientific oversight for these validated assays during their application in production studies. This encompasses a broad range of clinical trial phases, including preclinical studies, Phase I, and Phase II/III trials, to ensure that flow cytometry assays support the rigorous monitoring and evaluation required for successful drug development and clinical testing.